NDA 214793 · Progenics Pharms INC
Pylarify
Piflufolastat F-18 · Intravenous · Radioactive Diagnostic Agent
NovelPriority reviewCDER novel approval, May 26, 2021: To identify prostate-specific membrane antigen-positive lesions in prostate cancer
Last checked: Nov 20, 2026Latest source record: May 26, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
May 26, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
57
6 Phase 3, 11 recruiting
FAERS reports
334
14 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 18, 2026.
PYLARIFY is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. PYLARIFY is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. ( 1 )
Mechanism: Piflufolastat F 18 binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Fluorine-18 (F 18) is a β+ emitting radionuclide that enables positron emission tomography.
Therapeutic areas: Oncology · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 26, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
- PYLARIFY · PIFLUFOLASTAT F-18 50ML (1-80mCi/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Piflufolastat F-18" as an intervention, any sponsor and status, largest first.
- 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate CancerActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03181867 · 385 participants · Start Aug 3, 2017 · Primary completion Feb 1, 2031
Drug: 18F-DCFPyL; 18F-FDG and 1 more · For: Prostate Neoplasms; Prostatic Cancer; Prostate Cancer and 2 more
Sites: Bethesda, Maryland
- Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate CancerPivotal-lookingCompleted
Progenics Pharmaceuticals, Inc.Industry
NCT02981368 · 385 participants · Start Nov 2016 · Primary completion Jul 2018
Drug: 18F-DCFPyL Injection · For: Prostate Cancer
Sites: San Francisco, California; New Haven, Connecticut; Chicago, Illinois · 10 sites in all
Lantheus Medical ImagingIndustry
NCT06074510 · 279 participants · Start Feb 8, 2024 · Primary completion Aug 28, 2026
Drug: Piflufolastat F 18 Intravenous Solution [PYLARIFY] · For: Prostate Cancer
Sites: Birmingham, Alabama; Irvine, California; Los Angeles, California · 14 sites in all
VA Greater Los Angeles Healthcare SystemFederal agency
NCT04390880 · 239 participants · Start Apr 7, 2020 · Primary completion Aug 31, 2021
Drug: 18F-DCFPyL · For: Prostate Cancer
Sites: Los Angeles, California
- Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate CancerPivotal-lookingCompleted
Progenics Pharmaceuticals, Inc.Industry
NCT03739684 · 208 participants · Start Nov 27, 2018 · Primary completion Aug 29, 2019
Drug: 18F-DCFPyL · For: Prostate Cancer; Prostate Adenocarcinoma; Prostate Cancer Recurrent and 1 more
Sites: Duarte, California; Los Angeles, California; San Francisco, California · 14 sites in all
Akiva MintzAcademic, hospital or other
NCT06904313 · 200 participants (planned) · Start May 12, 2025 · Primary completion Jun 30, 2030
Drug: Piflufolastat F18 · For: Healthy Volunteer; Prostate CA
Sites: Englewood, New Jersey
- Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate CancerActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03976843 · 175 participants · Start Dec 4, 2019 · Primary completion Nov 19, 2027
Drug: 18F-DCFPyL · For: Prostate Cancer
Sites: New Orleans, Louisiana; Baltimore, Maryland; Bethesda, Maryland · 6 sites in all
- 18F-DCFPyL PET-CT Scan and Prostate CancerPivotal-lookingStatus unknown
Lida JafariFederal agency
NCT03852654 · 170 participants (planned) · Start Jul 22, 2018 · Primary completion Dec 30, 2019
Drug: 18F-DCFPyL · For: Prostate Cancer Adenocarcinoma
Sites: Los Angeles, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- radioisotope scan abnormal104
- drug ineffective75
- product dispensing error36
- product dose omission issue32
- underdose30
- product dispensing issue29
- intercepted product administration error26
- intercepted product dispensing error22
- product preparation error15
- occupational exposure to radiation8
- wrong product administered8
- dizziness7
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 6 |
| 2022 | 31 |
| 2023 | 55 |
| 2024 | 24 |
| 2025 | 78 |
| 2026 | 140 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Progenics Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.